Pituitary Prolactin-Secreting Tumor Formation: Recent Developments

NeuroSignals

Volumn 9, Issue 1, 2000, Pages 1-20

  Xu, R K ^a   Wu, X M ^a   Di, A K ^a   Xu, J N ^a   Pang, C S ^b   Pang, S F ^b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dopamine; E2 induced prolactinoma rat; Hypothalamus; Melatonin receptor; Pineal

Indexed keywords

2 AMINOBUTYRIC ACID; BROMOCRIPTINE; CABERGOLINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; ESTROGEN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MELATONIN; MELATONIN RECEPTOR; NEUROPEPTIDE; PIRIBEDIL; PROLACTIN; QUINAGOLIDE; ROXINDOLE; TRANSFORMING GROWTH FACTOR;

ANIMAL MODEL; CARCINOGENESIS; GENE MUTATION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HYPOTHALAMUS; NONHUMAN; PINEAL BODY; PROLACTINOMA; PROTEIN METHYLATION; PROTO ONCOGENE; RAT; REVIEW;

ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA; DNA METHYLATION; ESTRADIOL; FEMALE; HUMANS; MALE; MELATONIN; MUTATION; NEUROPEPTIDES; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROTO-ONCOGENES; RATS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 0033998901     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000014618     Document Type: Article

References (108)

1. Salman M: Tumors of the pituitary gland; in Moossa AR (ed): Oncology. Baltimore, Williams & Wilkins, 1986, pp 630-640.
2. Kovacs K, Horvath E: Pathology of pituitary tumors. Endocrinol Metab Clin North Am 1987;16:529-551.
3. Aron DC, Tyrrell JB, Wilson CB: Pituitary tumors. Current concepts in diagnosis and management. West J Med 1995;162:340-352.
4. Greenman Y, Tordjman K, Stern N: Increased body weight associated with prolactin secreting pituitary adenomas: Weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998;48:547-553.
5. Ciccarelli E, Camanni F: Diagnosis and drug therapy of prolactinoma. Drugs 1996;51:954-965.
6. Besser M: Criteria for medical as opposed to surgical treatment of prolactinomas. Acta Endocrinol (Copenh) 1993;129(suppl 1):27-30.
7. Tyson D, Reggiardo D, Sklar C, David R: Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 1993; 147: 1057-1061.
8. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbes-sem G, Scanlon MF: Treatment of macroprolactinoma with cabergol-ine: A study of 85 patients. Clin Endocrinol (Oxf) 1997;46:409-413.
9. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergol-ine. J Clin Endocrinol Metab 1996; 81:2338-2343.
10. Glaser B, Nesher Y, Barziliai S: Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502. J Reprod Med 1994;39:449-454.
11. Jaspers C, Benker G, Reinwein D: Treatment of prolactinoma patients with new non-ergot dopamine agonist roxindol: First results. Clin Invest 1994;72:451-456.
12. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A: Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994; 60:314-322.
13. Kahn SR, Leblanc R, Sadikot AF, Fantus IG: Marked hyperprolactinemia caused by carotid aneurysm. Can J Neurol Sci 1997;4:64-66.
14. Stepien H, Grochal M, Zielinski KW, Mucha S, Kunert-Radek J, Ku-lig A, Stawowy A, Pisarek H: Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 1996; 150:99-106.
15. Walsh JP, Pullan PT: Hyperprolac-tinaemia in males: A heterogeneous disorder. Aust NZ J Med 1997;27: 385-390.
16. Blackwell RE: Hyperprolactinemia. Evaluation and management. Endocrinol Metab Clin North Am 1992; 21:105-124.
17. Katznelson L, Klibanski A: Prolactinomas. Cancer Treat Res 1997;89: 41-55.
18. Wilson CB: Surgical management of pituitary tumors. J Clin Endocrinol Metab 1997;82:2381-2385.
19. Colao A, Annunziato L, Lombardi G: Treatment of prolactinomas. Ann Med 1998;30:452-459.
20. Missale C, Spano PF: Growth factors in the pathogenesis of prolactin-secreting tumors. J Endocrinol Invest 1998;21:402-411.
21. Molitch ME: Diagnosis and treatment of prolactinomas. Adv Intern Med 1999;44:117-153.
22. Clifton K, Meyer RK: Mechanisms of anterior pituitary tumors induction by estrogen. Anat Rec 1956; 125:65-81.
23. Lloyd RV: Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland: An immunohis-tochemical study. Am J Pathol 1983;113:198-206.
24. Holtzman S, Stone JP, Shellabarger CJ: Influence of diethylstilbestrol treatment on prolactin cells of female ACI and Sprague-Dawley rats. Cancer Res 1979;39:779-784.
25. Jacobi JM, Lloyd HM: Modulation by dopamine antagonists of DNA synthesis in the pituitary gland of the male rat. Neuroendocrinology 1981;33:97-100.
26. Eljarmak D, Lis M, Cantin M, Car-riere PD, Collu R: Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma. Horm Res 1985;21:160-167.
27. Weiner RI, Elias KA, Monnet F: The role of vascular changes in the etiology of prolactin-secreting anterior pituitary tumors; in MacLeod RM, Thorner MO, Scapagnini U (eds): Prolactin. Basic and Clinical Correlates. Fidia Reserch Series, Padova, Liviana, 1985, vol 1, pp 641-653.
28. Otto CA, Marshall JC, Lloyd RV, Sherman PS, Fisher SJ, Valoppi VL, Rogers WL, Wieland DM: Use of DES-treated rats as an animal model for assessment of pituitary adenoma imaging agents. Int J Rad Appl Instrum B 1986;13:539-547.
29. Maas DL, Martinson DR, Erdmann MD, Wahle JS, Hagen TC: Dynamics of prolactin secretion from di-ethylstilbestrol-induced rat prolactinoma tissue in vitro. Proc Soc Exp Biol Med 1995;210:150-155.
30. Asa SL, Pens G, Kovacs K, Ezrin C: Prolactin cells in the human pituitary. A quantitative immunocyto-chemical analysis. Arch Pathol Lab Med 1982;106:360-363.
31. Wu XM, Xu RK, Huang MY, Shan HM: 17-P-Estradiol-induced prolactin-secreting tumor formation of heteroplasty pituitary in renal capsule of the rats. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1998; 20:257-263.
32. Lloyd RV, Chandler WF, Kovacs K, Ryan N: Ectopic pituitary adenomas with normal anterior pituitary glands. Am J Surg Pathol 1986; 10: 546-552.
33. Tamaki N, Shirakuni T, Kokunai T, Matsumoto S, Fujimori T, Maeda S: Ectopic pituitary adenoma in the suprasellar cistern: Case report. Surg Neurol 1991;35:389-394.
34. Hattori N, Ishihara T, Saiwai S, Mo-ridera K, Hino M, Ikekubo K, Kura-hachi H: Ectopic prolactinoma on MRI. J Comput Assist Tomogr 1994;18:936-938.
35. Livingstone JD, Lerant A, Freeman ME: Ovarian steroids modulate responsiveness to dopamine and expression of G-proteins in lacto-tropes. Neuroendocrinology 1998; 68:172-179.
36. McCann SM, Lumpkin MD, Mizu-numa H, Khorram O, Samson WK: Recent studies on the role of brain peptides in control of anterior pituitary hormone secretion. Peptides 1984;5:3-7.
37. Fine SA, Frohman LA: Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J Clin Invest 1978;61:973-980.
38. Van Loon GR: A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma. Lancet 1978;Vol ii:868-871.
39. Albaladejo V, Collu R, Ander J: Down-regulation by 17-P-estradiol of D2 dopamine receptors in the MtTF4 pituitary tumor. Endocrinology 1984;114:2344-2348.
40. Bevan JS, Webster J, Burke CW, Scanlon MF: Dopamine agonists and pituitary tumor shrinkage. En-docr Rev 1992;13:220-240.
41. Roy D, Weisz J, Liehr JG: The O-methylation of 4-hydroxyestradiol is inhibited by 2-hydroxyestradiol: Implications for estrogen-induced carcinogenesis. Carcinogenesis 1990; 11:459-462.
42. 2 and its metabolites on the proliferation of rat anterior pituitary cells in vitro. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1997; 19:424-429.
43. Fernandez-Ruiz JJ, Alvarez-Sanz C, Ramos JA: 2-Hydroxyestradiol is not mediating the effects of estradiol on tuberoinfundibular dopaminergic neurons controlling prolactin secretion in female rats. J Steroid Bio-chem 1989;32:71-75.
44. Ferreira SA, Browning DA, Scott CJ, Kuehl DE, Jackson GL: Effect of infusing gamma-aminobutyric acid receptor agonists and antagonists into the medial preoptic area and ventromedial hypothalamus on prolactin secretion in male sheep. Endocrine 1998;9:303-312.
45. Li YL, Xu RK, Huang W, Shan HM: Effects of TRH and GABA on the expression of prolactin gene in anterior pituitary cells of rats. Basic Med Sci Clin 1994;14:314.
46. Veldhuis JD, Worgul TJ, Monsaert R, Hammond JM: A possible role of endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human. J Endocrinol Invest 1981;4:31-36.
47. Kato Y, Shimatsu A, Matsushita N, Ohta H, Imura H: Role of vasoactive intestinal polypeptide (VIP) in regulating the pituitary function in man. Peptides 1984;5:389-394.
48. Kaji H, Chihara K, Kita T, Kashio Y, Okimura Y, Fujita T: Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma. Acta Endocrinol (Copenh) 1985; 110:445-450.
49. Yamaji T, Ishibashi M, Teramoto A, Fukushima T: Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture. Acta Endocrinol (Copenh) 1985;108:456-463.
50. Lafond J, Collu R: Effects of repeated stimuli on prolactin release in vitro from normal and adenomatous rat lactotrophs. Mol Cell Endocrinol 1986;47:175-181.
51. Xu RK, Arisawa M, Yu MM, McCann SM: Effects of intraventricular synthetic ACTH (1-24) on secretion of anterior pituitary hormone and a mechanism of its action. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1988;10:249-253.
52. Ebenezer IS, Thornton SN, Parrott RF: Anterior and posterior pituitary hormone release induced in sheep by cholecystokinin. Am J Physiol 1989;256:R1355-R1357.
53. Xu RK McCann SM: Differential effects of naloxone on basal and stress-induced release of ACTH and prolactin in the male rat. Life Sci 1989;45:1591-1599.
54. Xu RK, Chen L, Li H, Yang SJ, Huang XY: Effects of K-opiate receptor antagonist MR-2266-BS on ACTH and prolactin release. Acta Physiol Sinica 1989;41:395-401.
55. Xu RK, Quan L, Huang MY, Yang SJ, Shi ZX, Huang XY: Influence of gastrin on secretion of prolactin and beta-endorphin in anterior pituitary. Basic Med Sci Clin 1991; 11: 273-277.
56. Xu RK, Huang MY, Yang SJ, Quan L, Shi ZX, Huang XY: Gastrinreleasing peptide regulates secretion of beta-endorphin and prolactin in anterior pituitary. Basic Med Sci Clin 1991;11:365-369.
57. Han XS, Xu RK, Huang MY, Zhou YZ, Shan HM, Guo CH, Huang XY: Effects of angiotensin II on prolactin and beta-endorphin release in male rats. Basic Med Sci Clin 1992; 12:360-365.
58. Xu RK, Huang MY, Quan L, Yang SJ, Shi ZX, Huang XY: Activation of 8-opiate receptor simultaneously stimulates ACTH, beta-endorphin and prolactin release. Chung Kuo I Hsueh, Ko Hsueh Yuan Hsueh Pao 1992;14:105-109.
59. Xu RK, Han XS, Huang MY, Zhou YZ, Shan HM, Guo CH, Huang XY: Vasoactive intestinal polypeptide in the control of prolactin and beta-endorphin release and its mechanism. Basic Med Sci Clin 1992;12:353-359.
60. Xu RK, Huang MY, Han CX, Guo CH, Zhou YZ, Huang XY: Pancreatic polypeptide in the control of beta-endorphin and prolactin release from rat anterior pituitary in vivo and in vitro (in Chinese). Sheng Li Hsueh Pao 1993;45:215-222.
61. Di AK, Shan HM, Huang MY, Xu RK: The effects of gastrin-releasing peptide and VIP on the prolactin gene transcription of pituitary PRL-secreting tumor of rat. Acta Physiol Sinica 196;49:79-87.
62. Zhou YZ, Huang MY, Shan HM, Han XS, Xu RK: Effects of chole-cystokinin on prolactin release and its action mechanism in the rats. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995;17:412-417.
63. Xu RK, Zhou YZ, Huang MY, Shan HM, Wang Y, Guo CH: Regulatory action of galanin on the release of prolactin and beta-endorphin from anterior pituitary of the rat. Chin J Physiol Sci 1996;12:57-63.
64. Parrott RF, Ebenezer IS, Baldwin BA, Buttle HL: Intravenous administration of cholecystokinin (CCK) stimulates prolactin and growth hor-one release in the pig. Methods Find Exp Clin Pharmacol 1995; 17:529-533.
65. Kellner M, Yassouridis A, Jahn H, Wiedemann K: Influence of cloni-dine on psychopathological, endocrine and respiratory effects of cho-lecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology (Berl) 1997;133:55-61.
66. 2+ mobilization and prolactin release in normal and hyperplastic pituitary cells. Am J Physiol 1998;274:E534-E540.
67. Lam KS: Vasoactive intestinal peptide in the hypothalamus and pituitary. Neuroendocrinology 1991; 53(suppl 1):45-51.
68. Samson WK, Lumpkin MD, McDonald JK, McCann SM: Prolactin releasing activity of porcine intestinal peptide (PH1-27). Peptides 1983;4:817-819.
69. McCann SM, Pan G, Xu RK, Marti-novic J, Rettor V: Modulatory hypothalamic action of ACTH on ACTH and prolactin release; in Hoshino K (ed): Prolactin Gene Family and Its Receptors. Amsterdam, Excerpta Medica, 1988, pp 211-218.
70. Di AK, Xu RK, Shan MH, Huang MY, Zhou YZ, Wang Y: The comparison of vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI) in the control of prolactin gene transcription. Basic Med Sci Clin 1995;15:355-359.
71. Xu RK, Quan L, Yang SJ, Shi ZX, Huang XY: Stimulation of ACTH, beta-endorphin and prolactin release by activation of 8-opiate receptor. Third IBRO World Congress of Neuroscience 1991, pp 33.26.
72. Maas DL, Meier DA, Wahle JS, Martinson DR, Hagen TC: Vasoactive intestinal polypeptide antiserum affects rat prolactin mRNA in 40-day but not 110-day diethylstil-bestrol-induced prolactinoma tissue. Mol Cell Neurosci 1994;5:182-188.
73. Makowska A, Zgliczynski W, Slo-winska-Srzednicka J, Soszynski P, Zgliczynski S: Increased plasma VIP concentration in patients with prolactinoma. Endokrynol Pol 1992;43: 230-233.
74. Tater D, Charpentier G, Besson G, Rosselin G, Bercovici J: VIP removes the inhibition of prolactin secretion induced by dopamine in patients with prolactinoma. CR Seances Acad Sci III 1983;297:331-334.
75. Gubbins EJ, Maurer RA, Lagrimini M, Erwin CR, Donelson JE: Structure of the rat prolactin gene. J Biol Chem 1980;255:8655-8662.
76. Cooke NE, Baxter JD: Structural analysis of the prolactin gene suggests a separate origin for its 5’ end. Nature 1982;279:603-606.
77. Berwaer M, Monget P, Peers B, Ma-thy-Harter M, Bellefroid E, Davis JR, Belayew A, Martial JA, Martial JA: Multihormonal regulation of the human prolactin gene expression from 5000 bp of its upstream sequence. Mol Cell Endocrinol 1991; 80:53-64.
78. Gourdji D, Laverriere JN: The rat prolactin gene: A target for tissue-specific and hormone-dependent transcription factors. Mol Cell Endocrinol 1994;100:133-142.
79. Di AK, Xu RK, Zhou YZ, Shan HM, Huang MY, Wu XM: Hypo-methylation of CpG sites in exon 1, 2 and 4 of prolactin gene of pituitary prolactinoma induced by estradiol in SD rat. Basic Med Sci Clin 1997; 17:430-435.
80. Lloyd RV, Osamura RY: Transcription factors in normal and neoplastic pituitary tissues. Microsc Res Tech 1997;39:168-181.
81. Guo CH, Xu RK, Huang MY, Shan HM: The expression of prolactin gene in the rat prolactinoma induced by 17-P-estradiol. Basic Med Sci Clin 1993;13:425-429.
82. Xu RK, Guo CH, Huang MY, Shan HM: Induction of rat prolactinoma by 17-P-estradiol and its relation to expression of c-myc oncogene. Dev Reprod Biol 1995;4:64-69.
83. Wu XM, Xu RK, Di AK, Shan HM, Huang MY: Differential expression of prolactin and transforming growth factor gene in eutopic and transplanted pituitary prolactinoma induced by 17-P-estradiol in SD rat. Sheng Li Hsueh Pao, in press.
84. Chernavsky AC, Valerani AV, Burdman JA: Haloperidol and oes-trogens induce c-myc and c-fos expression in the anterior pituitary gland of the rat. Neurol Res 1993; 15:339-343.
85. Szijan, I Parma DL, Engel NI: Expression of c-myc and c-fos protooncogenes in the anterior pituitary gland of the rat. Effect of estrogen. Horm Metab Res 1992;24:154-157.
86. Chernavsky AC, Chervin A, Vitale M, Basso A, Burdman JA: Human pituitary tumours: Studies on genes expression. Neurol Res 1993; 15:26.
87. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH: Metastatic prolactinoma: Effect of octreotide, cabergoline, carboplatin and etoposide: Immunocytochemi-cal analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;82:2962-2965.
88. Machiavelli GA, Rivolta CM, Ar-tese R, Basso A, Burdman JA: Expression of c-myc and c-fos and binding sites for estradiol and progesterone in human pituitary tumors. Neurol Res 1998;20:709-712.
89. Zhou YZ, Yu RK, Huang MY, Shan HM, Wu XM, Di AK: Reconstruction and application of eukaryotic expression plasmid of rat prolactin gene. Chin J Appl Physiol 1998; 14: 304-311.
90. Di AK, Xu RK, Wu W, Huang MY, Shan HM, Zhou YZ: The prolactin gene is highly sensitive to digestion by DNase I in the chromatin of anterior pituitary tumor induced by estradiol. Basic Med Sci Clin 1998; 18: 105-108.
91. Wu W, Xu RK, Di AK, Shan HM, Huang MY: A point mutation of prolactin gene in E2-induced pituitary prolactinoma formation. Chin Sci Bull, in press.
92. Shimon I, Huttner A, Said J, Spirina OM, Melmed S: Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumori-genesis and induces prolactin gene transcription. J Clin Invest 1996;97: 187-195.
93. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT, Klibanski A: ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 1994;78:89-93.
94. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL: Ras mutations in human pituitary tumors. J Clin Endocrinol Me-tab 1992;74:914-919.
95. Herman V, Drazin NZ, Gonsky R, Melmed S: Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-55.
96. Reiter RJ: The melatonin rhythm: Both a clock and a calendar. Experi-entia 1993;49:654-664.
97. Howes KA, Menendez-Pelaez A, Reiter RJ, Vaughan MK, Hensel CH, Vaughan GM: Serum luteinizing hormone, prolactin, and thyrotropin and their pituitary subunit mRNA levels during proestrus in the Syrian hamster. Neuroendocrinology 1991;54:629-634.
98. Esquifino AI, Villanua MA, Agrasal C, Reiter RJ, Tresguerres JA: Melatonin effects on prolactin secretion in pituitary-grafted female rats. J Endocrinol Invest 1989; 12:171-176.
99. Leadem CA, Burns DM: The inhibitory effects of light deprivation and the pineal gland on prolactin-secreting pituitary tumor in Fisher 344 rats; in Gupta D, Attanasio A, Reiter RJ (eds): The Pineal Gland and Cancer. Brain Res Promotion, London, 1988, pp 283-294.
100. Bartsch H, Bartsch C, Simon WE: Antitumor activity of the pineal gland: Effect of unidentified substances versus the effect of melatonin. Oncology 1992;49:27-30.
101. Panzer A, Viljoen M: The validity of melatonin as an oncostatic agent. J Pineal Res 1997;22:184-202.
102. Bubenik GA, Blask DE, Brown GM, Maestroni GJ, Pang SF, Reiter RJ, Viswanathan M, Zisapel N: Prospects of the clinical utilization of melatonin. Biol Signals Recept 1998;7:195-219.
103. Blask DE, Sauer LA, Dauchy R, Holowachuk EW, Ruhoff MS: New actions of melatonin on tumor metabolism and growth. Biol Signals Recept 1999;8:49-55.
104. Karasek M, Pawlikowski M: Antiproliferative effects of melatonin and CGP 52608. Biol Signals Re-cept 1999;8:75-78.
105. Di AK, Xu RK, Pang SF, Shan HM, Pang CS, Qian ZM, Huang MY: Melatonin inhibits TRH-stimulating prolactin gene expression of anterior pituitary cell in newborn rat in vitro. Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1997;19:430-434.
106. Reppert SM: Melatonin receptors: Molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997;12:528-531.
107. Shiu SY, Pang SF: An updated phylogenetic analysis of vertebrate melatonin receptor sequences: Reflection on the melatonin receptor nomenclature by the Nomenclature Subcommittee of the International Union of Pharmacology. Biol Signals Recept 1998;7:244-248.
108. Xu RK, Di AK, Qian ZNI, Tang PL, Pang CS, Pang SF: Evidence for the existence of the Mel-1b melatonin receptor expressed in rat anterior pituitary and adrenal. Asia Pacific Pineal Meeting, Melatonin: 40 Years after Discovery, Hamamatsu, 1997, pp 75.